Daytime sleepiness and sleep quality in Charcot-Marie-Tooth disease.


Journal

Journal of neurology
ISSN: 1432-1459
Titre abrégé: J Neurol
Pays: Germany
ID NLM: 0423161

Informations de publication

Date de publication:
Nov 2023
Historique:
received: 21 04 2023
accepted: 28 07 2023
revised: 05 07 2023
medline: 23 10 2023
pubmed: 4 8 2023
entrez: 4 8 2023
Statut: ppublish

Résumé

Sleep abnormalities have been reported in Charcot-Marie-Tooth disease (CMT), but data are scanty. We investigated their presence and correlation in a large CMT patients' series. Epworth Sleepiness Scale (ESS) and Pittsburgh Sleep Quality Index (PSQI) were administered to CMT patients of the Italian registry and controls. ESS score > 10 indicated abnormal daytime somnolence, PSQI score > 5 bad sleep quality. We analyzed correlation with disease severity and characteristics, Hospital Anxiety and Depression Scale (HADS), Modified Fatigue Impact Scale (MFIS), Body Mass Index, drug use. ESS and PSQI questionnaires were filled by 257 and 253 CMT patients, respectively, and 58 controls. Median PSQI score was higher in CMT patients than controls (6 vs 4, p = 0.006), with no difference for ESS score. Abnormal somnolence and poor sleep quality occurred in 23% and 56% of patients; such patients had more frequently anxiety/depression, abnormal fatigue, and positive sensory symptoms than those with normal ESS/PSQI. Moreover, patients with PSQI score > 5 had more severe disease (median CMT Examination Score, CMTES, 8 vs 6, p = 0.006) and more frequent use of anxiolytic/antidepressant drugs (29% vs 7%, p < 0.001). Bad sleep quality and daytime sleepiness are frequent in CMT and correlated with anxiety, depression and fatigue, confirming that different components affect sleep. Sleep disorders, such as sleep apnea and restless leg syndrome, not specifically investigated here, are other factors known to impact on sleep quality and somnolence. CMT patients' management must include sleep behavior assessment and evaluation of its correlated factors, including general distress and fatigue.

Sections du résumé

BACKGROUND BACKGROUND
Sleep abnormalities have been reported in Charcot-Marie-Tooth disease (CMT), but data are scanty. We investigated their presence and correlation in a large CMT patients' series.
METHODS METHODS
Epworth Sleepiness Scale (ESS) and Pittsburgh Sleep Quality Index (PSQI) were administered to CMT patients of the Italian registry and controls. ESS score > 10 indicated abnormal daytime somnolence, PSQI score > 5 bad sleep quality. We analyzed correlation with disease severity and characteristics, Hospital Anxiety and Depression Scale (HADS), Modified Fatigue Impact Scale (MFIS), Body Mass Index, drug use.
RESULTS RESULTS
ESS and PSQI questionnaires were filled by 257 and 253 CMT patients, respectively, and 58 controls. Median PSQI score was higher in CMT patients than controls (6 vs 4, p = 0.006), with no difference for ESS score. Abnormal somnolence and poor sleep quality occurred in 23% and 56% of patients; such patients had more frequently anxiety/depression, abnormal fatigue, and positive sensory symptoms than those with normal ESS/PSQI. Moreover, patients with PSQI score > 5 had more severe disease (median CMT Examination Score, CMTES, 8 vs 6, p = 0.006) and more frequent use of anxiolytic/antidepressant drugs (29% vs 7%, p < 0.001).
CONCLUSIONS CONCLUSIONS
Bad sleep quality and daytime sleepiness are frequent in CMT and correlated with anxiety, depression and fatigue, confirming that different components affect sleep. Sleep disorders, such as sleep apnea and restless leg syndrome, not specifically investigated here, are other factors known to impact on sleep quality and somnolence. CMT patients' management must include sleep behavior assessment and evaluation of its correlated factors, including general distress and fatigue.

Identifiants

pubmed: 37540277
doi: 10.1007/s00415-023-11911-y
pii: 10.1007/s00415-023-11911-y
pmc: PMC10576706
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

5561-5568

Subventions

Organisme : Fondazione Telethon
ID : GUP13006

Investigateurs

Giulia Schirinzi (G)
Maria Montesano (M)
Sara Nuzzo (S)
Francesca Oggiano (F)
Daniela Calabrese (D)
Chiara Gemelli (C)
Yuri Falzone (Y)
Emanuele Spina (E)
Maria Longo (M)
Giuseppe Occhipinti (G)
Giacomo Iabichella (G)
Stefania Barone (S)

Commentaires et corrections

Type : ErratumIn

Informations de copyright

© 2023. The Author(s).

Références

J Neurol Neurosurg Psychiatry. 2014 Mar;85(3):319-25
pubmed: 23704315
Lancet. 2001 Jan 27;357(9252):267-72
pubmed: 11214130
Epilepsy Behav. 2021 Aug;121(Pt A):108099
pubmed: 34102473
Br J Cancer. 2009 Mar 24;100(6):908-12
pubmed: 19240713
Eur J Neurol. 2023 Aug;30(8):2461-2470
pubmed: 37170966
Mult Scler. 2005 Feb;11(1):76-80
pubmed: 15732270
J Neurol. 2010 Apr;257(4):646-52
pubmed: 19937049
Neurology. 1999 Mar 23;52(5):1064-6
pubmed: 10102430
Support Care Cancer. 1999 May;7(3):121-7
pubmed: 10335929
J Neurol Neurosurg Psychiatry. 2010 Sep;81(9):963-7
pubmed: 20798200
J Neurol Neurosurg Psychiatry. 1998 Apr;64(4):510-5
pubmed: 9576545
Mult Scler. 2002 Dec;8(6):523-6
pubmed: 12474995
J Clin Sleep Med. 2015 Mar 15;11(3):205-11
pubmed: 25515278
Psychiatry Res. 1989 May;28(2):193-213
pubmed: 2748771
Chronobiol Int. 2018 Apr;35(4):533-545
pubmed: 29341789
Orphanet J Rare Dis. 2018 Oct 4;13(1):176
pubmed: 30286784
J Neurol Neurosurg Psychiatry. 2008 Jul;79(7):829-31
pubmed: 18559462
Neurol Sci. 2013 Apr;34(4):511-9
pubmed: 22526760
J Peripher Nerv Syst. 2011 Sep;16(3):191-8
pubmed: 22003934
Sleep Sci. 2022 Jan-Mar;15(1):41-46
pubmed: 35662969
J Neurol Sci. 2009 Dec 15;287(1-2):36-40
pubmed: 19804890
J Neurol Neurosurg Psychiatry. 2008 Jul;79(7):743-4
pubmed: 18559457
J Neurol. 2023 Jan;270(1):394-401
pubmed: 36114297
Sleep. 1991 Dec;14(6):540-5
pubmed: 1798888
J Neurol. 1999 Apr;246(4):275-82
pubmed: 10367695
Expert Rev Neurother. 2021 Jun;21(6):701-713
pubmed: 34033725
Eur J Neurol. 2023 Mar;30(3):710-718
pubmed: 36458502
Neurol Sci. 2003 Feb;23(6):295-300
pubmed: 12624716

Auteurs

Marta Bellofatto (M)

SC Malattie Neurologiche Rare, Dipartimento di Neuroscienze Cliniche, Fondazione IRCCS Istituto Neurologico Carlo Besta, Via Celoria 11, 20133, Milan, Italy.

Luca Gentile (L)

Unità di Neurologia e Malattie Neuromuscolari, Dipartimento di Medicina Clinica e Sperimentale, Università di Messina, 98124, Messina, Italy.

Alessandro Bertini (A)

SC Malattie Neurologiche Rare, Dipartimento di Neuroscienze Cliniche, Fondazione IRCCS Istituto Neurologico Carlo Besta, Via Celoria 11, 20133, Milan, Italy.

Irene Tramacere (I)

Dipartimento Gestionale di Ricerca e Sviluppo Clinico, Direzione Scientifica, Fondazione IRCCS Istituto Neurologico Carlo Besta, 20133, Milan, Italy.

Fiore Manganelli (F)

Dipartimento di Neuroscienze, Scienze Riproduttive ed Odontostomatologiche, Università Federico II di Napoli, 80131, Naples, Italy.

Gian Maria Fabrizi (GM)

Dipartimento di Neuroscienze, Biomedicina e Movimento, Università di Verona, 37126, Verona, Italy.

Angelo Schenone (A)

Dipartimento di Neuroscienze, Riabilitazione, Oftalmologia, Genetica e Scienze Materno-Infantili, Università di Genova, 16132, Genoa, Italy.
IRCCS Ospedale Policlinico San Martino, 16132, Genoa, Italy.

Lucio Santoro (L)

Dipartimento di Neuroscienze, Scienze Riproduttive ed Odontostomatologiche, Università Federico II di Napoli, 80131, Naples, Italy.

Tiziana Cavallaro (T)

Dipartimento di Neuroscienze, Biomedicina e Movimento, Università di Verona, 37126, Verona, Italy.

Marina Grandis (M)

Dipartimento di Neuroscienze, Riabilitazione, Oftalmologia, Genetica e Scienze Materno-Infantili, Università di Genova, 16132, Genoa, Italy.
IRCCS Ospedale Policlinico San Martino, 16132, Genoa, Italy.

Stefano C Previtali (SC)

INSPE and Division of Neuroscience, IRCCS Ospedale San Raffaele, 20132, Milan, Italy.

Marina Scarlato (M)

INSPE and Division of Neuroscience, IRCCS Ospedale San Raffaele, 20132, Milan, Italy.

Isabella Allegri (I)

U.O. Neurologia, A.O. di Parma, 42126, Parma, Italy.

Luca Padua (L)

Università Cattolica del Sacro Cuore, 00168, Rome, Italy.
Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168, Rome, Italy.

Costanza Pazzaglia (C)

Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168, Rome, Italy.

Flavio Villani (F)

Unità di U.O. Neurofisiopatologia, IRCCS Ospedale Policlinico San Martino, 16132, Genoa, Italy.

Eleonora Cavalca (E)

SC Malattie Neurologiche Rare, Dipartimento di Neuroscienze Cliniche, Fondazione IRCCS Istituto Neurologico Carlo Besta, Via Celoria 11, 20133, Milan, Italy.

Paola Saveri (P)

SC Malattie Neurologiche Rare, Dipartimento di Neuroscienze Cliniche, Fondazione IRCCS Istituto Neurologico Carlo Besta, Via Celoria 11, 20133, Milan, Italy.

Aldo Quattrone (A)

Dipartimento di Scienze Mediche, Università Magna Grecia, 88100, Catanzaro, Italy.

Paola Valentino (P)

Dipartimento di Scienze Mediche, Università Magna Grecia, 88100, Catanzaro, Italy.

Stefano Tozza (S)

Dipartimento di Neuroscienze, Scienze Riproduttive ed Odontostomatologiche, Università Federico II di Napoli, 80131, Naples, Italy.

Massimo Russo (M)

Unità di Neurologia e Malattie Neuromuscolari, Dipartimento di Medicina Clinica e Sperimentale, Università di Messina, 98124, Messina, Italy.

Anna Mazzeo (A)

Unità di Neurologia e Malattie Neuromuscolari, Dipartimento di Medicina Clinica e Sperimentale, Università di Messina, 98124, Messina, Italy.

Giuseppe Vita (G)

Unità di Neurologia e Malattie Neuromuscolari, Dipartimento di Medicina Clinica e Sperimentale, Università di Messina, 98124, Messina, Italy.

Sylvie Piacentini (S)

Unità di Neuropsicologia, Dipartimento di Neuroscienze Cliniche, Fondazione IRCCS Istituto Neurologico Carlo Besta di Milano, 20133, Milan, Italy.

Giuseppe Didato (G)

Unità di Epilettologia Clinica e Sperimentale, Dipartimento di Neuroscienze Cliniche, Fondazione IRCCS Istituto Neurologico Carlo Besta, 20133, Milan, Italy.

Chiara Pisciotta (C)

SC Malattie Neurologiche Rare, Dipartimento di Neuroscienze Cliniche, Fondazione IRCCS Istituto Neurologico Carlo Besta, Via Celoria 11, 20133, Milan, Italy.

Davide Pareyson (D)

SC Malattie Neurologiche Rare, Dipartimento di Neuroscienze Cliniche, Fondazione IRCCS Istituto Neurologico Carlo Besta, Via Celoria 11, 20133, Milan, Italy. davide.pareyson@istituto-besta.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH